NCT00421395已完成1 期
Phase I/II Radioimmunotherapy of Non-Hodgkin's Lymphoma With Radiolabeled Humanized IMMU-LL2: Treatment With 90Y-hLL2 IgG
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 59
- 试验地点
- 10
- 主要终点
- Safety will be evaluated from physical examinations, hematology and chemistry testing and toxicity evaluation
研究概览
简要总结
This will be an open label, multiple center, non-randomized, dose-escalation Phase I/II trial, designed to evaluate the safety and effectiveness of a repeated, outpatient regimen utilizing IMMU-hLL2 intact monoclonal antibody IgG labeled with different doses of 90Y for the treatment of patients B-cell lymphoma (NHL).
详细描述
90Y-labeled hLL2 will be administered according to a schedule based upon whether or not a patient had prior high-dose chemotherapy with a marrow or stem cell transplant. Patients with both indolent and aggressive types of NHL will be enrolled at each dose level without segregation. However, at the conclusion of the trial, with the maximum tolerated dose (MTD) defined, a minimum number of 6 patients with indolent NHL, 6 patients with aggressive NHL, and 6 patients with >25% bone marrow involvement will be studied at that dose level.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All patients must have a histologic or cytological diagnosis of B-cell lymphoma, and have failed at least one regimen of standard chemotherapy. All histologic grades of non-Hodgkin's lymphoma (NHL) will be eligible for these studies.
- •Patients must be > 18 years of age
- •Measurable disease by CT, with at least one lesion > 1.5 cm in one or both dimensions
- •less than 25% bone marrow involvement as determined by bone marrow biopsy
- •Patient must have greater than 15% cellularity of the bone marrow.
- •Patients must be at least 4 weeks beyond any major surgery.
- •Patients must be at least 4 weeks beyond any radiation therapy to the index lesion and must have recovered from radiation induced toxicity.
- •Patients must be at least 4 weeks beyond prior chemotherapy and/or immunotherapy, or 2-weeks after corticosteroids, and their blood counts must be within the eligibility criteria. Corticosteroids may, however, be given concomitantly if used to treat adrenal insufficiency
- •Patients must have a performance status of 70 or greater on the Karnofsky scale equivalent to ECOG 0-1 (See Appendix A) and a minimal life expectancy of 6 months.
- •Patients must be able to give cognizant informed consent.
排除标准
- •Patients with a significant concurrent medical complication including severe anorexia, nausea or vomiting that in the judgement of the Investigator could affect the patient's ability to tolerate or complete this study.
- •Patients with metastasis to the brain.
- •Patients with extensive irradiation to more than 25% of their red marrow will be excluded, except those who had total body irradiation in the context of bone marrow or stem cell transplantation regimen with subsequent engraftment of a functional marrow (i.e., resulting in normal peripheral blood counts). Subjects who have received external radiation to specific organs or areas at the maximum tolerated level are also excluded.
- •Women who test positive for pregnancy.
- •Patients with splenomegaly.
- •Patients with > 4 treatment regimens prior to this protocol, including chemotherapy, radiotherapy and/or other immunotherapy.
- •Patients with prior radioimmunotherapy treatments (unless for retreatment under this protocol).
- •Patients receiving rituximab within 3 months, unless progressing after treatment.
- •Patients with <50% LVEF by required MUGA or 2-D ECHO.
- •Patients with <60% of predicted value by required pulmonary function tests.
- •Patients who have active Hepatitis B or C or are known HIV positive.
- •Patients with another primary malignancy (except basal/squamous cell carcinoma of the skin or carcinoma in-situ of the cervix.
- •Patients with other serious medical, surgical, or psychiatric history, unless currently stable and well controlled, without significant increase in treatment medications for at least 30 days preceding study entry.
结局指标
主要结局
Safety will be evaluated from physical examinations, hematology and chemistry testing and toxicity evaluation
时间窗: First 12 weeks, total 5 years
次要结局
- Determine maximum tolerated dose (MTD)(first 12 weeks)
- Evaluate the immunogenicity and safety of repeated infusions of 90Y-hLL2 in NHL patients.(6 weeks, 12 weeks, every 3 months if HAHA elevated)
- Determine the therapeutic effects, in terms of objective response rate and duration, of the therapeutic agent in NHL patients.(6 wks, 12 wks, every 3 mos for 5 years)
研究者
研究点 (10)
Loading locations...
相似试验
已完成
1 期
Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgGNon-Hodgkin's LymphomaLymphoma, B-CellNCT00061425Gilead Sciences
已完成
2 期
Safety and Efficacy Therapy of Gemcitabine and Erbitux® to R0 or R1 Resected Pancreatic CancerAdenocarcinomaNCT00395252Carmen Schade-Brittinger76
终止
2 期
Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With MelanomaStage III MelanomaStage IV MelanomaNCT01026051Mannkind Corporation5
招募中
2 期
A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)Advanced or Metastatic Breast CancerNCT04742153Shanghai Miracogen Inc.66
已完成
2 期
Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer PatientsBreast CancerNCT02297698Cancer Insight, LLC100